



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/815,127	03/31/2004	Ashish A. Patel	G-33712P1	9219
1095 7550 04/15/2008				
NOVARTIS				
CORPORATE INTELLECTUAL PROPERTY				
ONE HEALTH PLAZA 104/3				
EAST HANOVER, NJ 07936-1080				
EXAMINER				
PURDY, KYLE A				
ART UNIT		PAPER NUMBER		
1611				
MAIL DATE		DELIVERY MODE		
04/15/2008		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/815,127

**Applicant(s)**

PATEL ET AL.

**Examiner**

Kyle Purdy

**Art Unit**

1611

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 03/31/2004, 08/15/2007 and 03/03/2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-8 and 10-29 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-8 and 10-29 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## DETAILED ACTION

### *Status of Application*

1. The Examiner acknowledges receipt of the amendments filed on March 3, 2008 wherein claims 1 and 18 have been amended and claim 9 has been cancelled.

2. Claims 1-8 and 10-29 are pending and presented for examination on the merits. The following rejections are made.

### *Response to Applicants' Arguments*

3. Applicants arguments filed March 3, 2008 regarding the rejection of claims 1-29 made by the Examiner under 35 USC 103(a) have been fully considered. This ground of rejections has been **WITHDRAWN** as being overcome by amendment.

### *New Grounds of Rejection Claim Rejections - 35 USC § 103*

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 1-8, 10, 12-13, 16 and 18-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over MacLaren et al. (US 6039974; of record) in view of Uemura et al. (US 4695467) and Stainforth et al. (US 5858412).

6. MacLaren et al. ('Maclaren') teaches a pharmaceutical composition that is a combination of piperidinoalkanol-decongestant wherein the composition is in the form of a bilayer tablet comprising two discrete zones (see abstract). It is taught formulation A is sustained release portion which comprises a decongestant (i.e. sympathomimetic drug), specifically that of pseudoephedrine which is present in an amount of 120 mg (see column 2, lines 32-40 and Table 1; see instant claim 29). Table 1 teaches that the sympathomimetic drug containing layer contains a carnuba wax, stearic acid and silicon dioxide.

7. Formulation B is an immediate release portion which comprises a piperidinoalkanol compound, specifically that of fexofenadine which is present in an amount of 60 mg (see column 2, lines 32-40 and Table 1; see instant claim 29). Fexofenadine is a widely used antihistamine, antiallergic agents and bronchodilator. Table 5 teaches that the fexofenadine containing portion of the tablet comprises among other ingredients a diluent (or filler), a disintegrant and a lubricant which are microcrystalline cellulose (functionally equivalent to lactose (see column 11, line 35)) from about 27% and 73%, croscarmellose sodium from about 0.25% and 6.0% by weight and magnesium stearate from about 0.25% to about 2.00%, respectively (see abstract).

8. It is also taught that Formulation A and Formulation B may contain excipients which are commonly used in the art such as binders, diluents, lubricants, glidants, disintegrants, etc.. It is taught that lubricant may be magnesium stearate and the diluent (or filler) may be lactose (see column 11, lines 20-40). MacLaren also teaches that the bilayer tablet may be coated (see Table 1).

9. Maclaren fails to teach the sustained release portion, Formulation A as comprising a filler from about 5% to about 20%, a cellulose binder at a weight percentage from about 20% to about

Art Unit: 1615

50%, ethylcellulose from about 10% to about 35% and from about 2% to about 50% of a wax and a lubricant from about 0.5% to about 2%.

10. The teaching of Uemura et al. ('Uemura) is directed to a sustained release tablet formulation. The sustained release formulation comprises granules comprising a drug, a disintegrating agent and a water soluble polymer (see abstract). Example 3 teaches a formulation for a sustained release formulation which comprises a drug, low substituted hydroxypropyl cellulose (binder) at a weight percentage of 23%, hydroxypropyl methylcellulose (binder), lactose (filler) at a weight percentage of 7.5%, carnuba wax (wax) at a weight percent of 25% and magnesium stearate (lubricant) at a weight percent of 0.2%.

11. The teaching of Stainforth et al. ('Stainforth) is drawn to sustained release formulations utilizing pharmaceutical excipients having improved compressibility. It is disclosed that suitable materials for use in sustained release tablet formulations includes alkylcelluloses such as ethylcellulose (see column 16, lines 50-55). It is taught that the tablet will preferably contain the alkyl cellulose between from about 1 to about 80% by weight of the sustained release dosage form (see column 18, line 20).

12. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have combined the teachings of MacLaren, Uemura and Stainforth with a reasonable expectation for success in arriving at a bilayer tablet comprising two discrete zones wherein discrete zone A is a sustained release zone which comprises 120 mg of pseudoephedrine and a filler (lactose), a cellulose binder (hydropropyl methylcellulose), ethylcellulose, between 2% to about 50% a wax (carnuba) and a lubricant (magnesium stearate) and wherein discrete zone B is an immediate release zone which comprises 60 mg of fexofenadine, a sugar (lactose),

Art Unit: 1615

disintegrant (croscarmellose sodium) and a lubricant (magnesium stearate) at the required weight percentages (see above). The significance of MacLaren is that it teaches the major inventive concept, a bilayer tablet in which one layer is a sustained release layer for pseudoephedrine and the other layer is an immediate release layer for fexofenadine wherein the fexfenadine layer further comprises a cellulose diluent, a disintegrant and a lubricant. Moreover, MacLaren teaches that the cellulose diluent (microcrystalline cellulose) is functionally equivalent to lactose (see above) as well as indicates that both portions of the tablet may include excipients such as lactose and magnesium stearate. MacLaren fails to teach portion A of the tablet comprising a filler, a cellulose binder, ethylcellulose, a wax and a lubricant at the specified weight percentages (see above). With respect to the inclusion of a wax from about 2 to 50% and the inclusion of a cellulose binder, a lubricant and a filler, the teaching of Uemura cures these deficiencies. Uemura teaches a formulation for a sustained release tablet comprising a cellulose binder, specifically low-substituted hydroxypropyl cellulose at a weight percentage of 23%, lactose at a weight percentage of 7.5%, a wax at a weight percentage of about 25%. With respect to the inclusion of ethylcellulose, the teaching of Stainforth cures this deficiency. Stainforth states that ethylcellulose is a commonly used carrier matrix in sustained release tablet formulations and can be used between 1-80 weight %. As all of these references are within the same general field of endeavor (i.e. adjusting the rate of release from a solid dosage form), one would have been motivated to combine the references and arrive at a product possessing the instantly claimed properties. It should be noted that the excipients which Applicant employs in their dosage forms are commonly used in tablet formulations (both immediate and sustained release formulations), and it would have been obvious to one ordinarily skilled in the art to adjust and vary the amounts

Art Unit: 1615

of the ingredients in the composition to arrive at a dosage form with the greatest therapeutic properties. Therefore, the invention as a whole is *prima facie* obvious to one ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in absence of evidence to the contrary.

**13. Claims 1 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over MacLaren et al. (US 6039974; of record) in view of Uemura et al. (US 4695467), Stainforth et al. (US 5858412) and Okada et al. (US 5164193).**

14. MacLaren, Uemura and Stainforth is relied upon for disclosure described in the rejection of claim 1 under 35 U.S.C. 103(a).

15. MacLaren, Uemura and Stainforth fails to teach the sustained release portion of the bilayer tablet (A) as comprising between 2% to about 50% stearyl alcohol.

16. The teaching of Okada et al. ('Okada) cures this deficiency. Okada is drawn to a sustained release tablet which comprises an oil or waxy component (see abstract). Many oily and waxy components are disclosed (see column 2 and column 3). It is disclosed that stearyl alcohol is a preferred alcohol (see column 3, line 20). Moreover, it is taught that in order to ensure the effect of the present invention that the oil component be present a weight percentage of 5.0% and greater (see column 4, line 10).

17. Therefore, it would have been obvious to one ordinarily skilled in the art at the time the invention was made to combine the teachings of MacLaren, Uemura, Stainforth and Okada with a reasonable expectation for success in arriving at a bilayer tablet in which the sustained release (A) portion comprises lactose (see above), hydroxypropylmethylcellulose (see above),

Art Unit: 1615

ethylcellulose (see above), stearyl alcohol at about 5.0 wt. % or above and magnesium stearate (see above). The significance of Okada is that it teaches stearyl alcohol as being a particularly preferred and a useful oily component for implementation in a sustained release formulation. Thus, one would have motivated to use stearyl in a sustained release composition or sustained portion of a bilayer tablet with a reasonable expectation for success.

**18. Claims 1, 14, 15 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over MacLaren et al. (US 6039974) in view of Uemura et al. (US 4695467), Stainforth et al. (US 5858412) and Bertelsen et al. (US 6713089).**

19. MacLaren, Uemura and Stainforth is relied upon for disclosure described in the rejection of claim 1 under 35 U.S.C. 103(a).

20. MacLaren, Uemura and Stainforth fails to teach the immediate release portion of the bilayer tablet (B) as comprising the disintegrant low-substituted hydroxypropyl cellulose wherein the low-substituted hydroxypropyl cellulose may be selected from a wide range of species with varying hydroxypropyl content and average particle size.

21. Bertelsen et al. ("Bertelsen") is drawn to rapid release formulations. It is disclosed that low-substituted hydroxypropyl cellulose is a useful disintegrant (see column 14, lines 35-55). Exemplified low-substituted hydroxycellulose include LH-20 and LH-21 (see column 14, line 55).

22. Therefore, it would have been obvious to one ordinarily skilled in the art at the time the invention was made to combine the teachings of MacLaren, Uemura, Stainforth and Bertelsen with a reasonable expectation for success in arriving at a bilayer tablet in which the immediate



Art Unit: 1615

release portion (B) comprises the disintegrant low-substituted hydroxypropyl cellulose (i.e. LH-20 or LH-21), a filler (lactose, see above) and a lubricant (magnesium stearate, see above). The significance of Bertelsen is that it teaches the inclusion of low-substituted hydroxypropyl cellulose in a rapid release formulation. Thus, one would have been motivated to use a low-substituted hydroxypropyl cellulose compound in a rapid release composition or rapid release portion of a bilayer tablet with a reasonable expectation for success.

### ***Conclusion***

23. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

24. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

25. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kyle A. Purdy whose telephone number is 571-270-3504. The examiner can normally be reached from 9AM to 5PM.

26. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

27. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*/Kyle Purdy/  
Examiner, Art Unit 1611  
April 11, 2008*

*/Michael P Woodward/  
Supervisory Patent Examiner, Art  
Unit 1615*